Chair’s Take on Innovation in Prostate Cancer: Thoughts on New Evidence

Chair’s Take on Innovation in Prostate Cancer: Thoughts on New Evidence is organized by PVI, PeerView Institute for Medical Education, Penn State College of Medicine.

Release Date: June 22, 2020
Expiration Date: June 21, 2021

Accreditation:
Physicians
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
In this activity, an expert in prostate cancer discusses recent developments in prostate cancer, including evidence presented at the 2020 ASCO Virtual Scientific Program, and offers thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer.

Educational Objectives
Upon completion of this activity, participants should be better able to:
• Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer
• Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers
• Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum
• Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer
• Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors